Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comparison of functional assays used in the clinical development of a placental malaria vaccine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fighting Cancer Using an Oncofetal Glycosaminoglycan-Binding Protein from Malaria Parasites

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: Malaria in pregnancy is associated with significant morbidity in pregnant women and their offspring. Plasmodium falciparum infected erythrocytes (IE) express VAR2CSA that mediates binding to chondroitin sulphate A (CSA) in the placenta. Two VAR2CSA-based vaccines for placental malaria are in clinical development. The purpose of this study was to evaluate the robustness and comparability of binding inhibition assays used in the clinical development of placental malaria vaccines.

METHODS: The ability of sera from animals immunised with different VAR2CSA constructs to inhibit IE binding to CSA was investigated in three in vitro assays using 96-well plates, petri dishes, capillary flow and an ex vivo placental perfusion assay.

RESULTS: The inter-assay variation was not uniform between assays and ranged from above ten-fold in the flow assay to two-fold in the perfusion assay. The intra-assay variation was highest in the petri dish assay. A positive correlation between IE binding avidity and the level of binding after antibody inhibition in the petri dish assay indicate that high avidity IE binding is more difficult to inhibit. The highest binding inhibition sensitivity was found in the 96-well and petri dish assays compared to the flow and perfusion assays where binding inhibition required higher antibody titers.

CONCLUSIONS: The inhibitory capacity of antibodies is not easily translated between assays and the high sensitivity of the 96-well and petri dish assays stresses the need for comparing serial dilutions of serum. Furthermore, IE binding avidity must be in the same range when comparing data from different days. There was an overall concordance in the capacity of antibody-mediated inhibition, when comparing the in vitro assays with the perfusion assay, which more closely represents in vivo conditions. Importantly the ID1-ID2a protein in a liposomal formulation, currently in a phase I trial, effectively induced antibodies that inhibited IE adhesion in placental tissue.

OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind35
Udgave nummer4
Sider (fra-til)610-618
Antal sider9
ISSN0264-410X
DOI
StatusUdgivet - 23 jan. 2017

ID: 52820997